GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (NAS:ONCT) » Definitions » E10

ONCT (Oncternal Therapeutics) E10 : $-209.39 (As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Oncternal Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Oncternal Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-2.860. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-209.39 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 18.40% per year. During the past 5 years, the average E10 Growth Rate was 12.30% per year. During the past 10 years, the average E10 Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Oncternal Therapeutics was 31.70% per year. The lowest was 3.60% per year. And the median was 16.60% per year.

As of today (2024-12-15), Oncternal Therapeutics's current stock price is $0.5266. Oncternal Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-209.39. Oncternal Therapeutics's Shiller PE Ratio of today is .


Oncternal Therapeutics E10 Historical Data

The historical data trend for Oncternal Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics E10 Chart

Oncternal Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -417.20 -489.01 -424.45 -373.76 -266.16

Oncternal Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -288.95 -266.16 -245.39 -219.44 -209.39

Competitive Comparison of Oncternal Therapeutics's E10

For the Biotechnology subindustry, Oncternal Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncternal Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Oncternal Therapeutics's Shiller PE Ratio falls into.



Oncternal Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncternal Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-2.86/133.0289*133.0289
=-2.860

Current CPI (Sep. 2024) = 133.0289.

Oncternal Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -182.000 99.070 -244.386
201503 -28.000 99.621 -37.390
201506 -476.000 100.684 -628.916
201509 -56.000 100.392 -74.206
201512 -56.000 99.792 -74.651
201603 21.000 100.470 27.805
201606 -60.200 101.688 -78.754
201609 -68.600 101.861 -89.591
201612 -61.600 101.863 -80.447
201703 -54.600 102.862 -70.613
201706 -56.000 103.349 -72.082
201709 -74.200 104.136 -94.787
201712 -60.200 104.011 -76.995
201803 -86.800 105.290 -109.668
201806 -60.200 106.317 -75.325
201809 -54.600 106.507 -68.196
201812 -30.800 105.998 -38.654
201903 -33.600 107.251 -41.676
201906 -67.600 108.070 -83.213
201909 -6.400 108.329 -7.859
201912 3.400 108.420 4.172
202003 -6.200 108.902 -7.574
202006 -6.800 108.767 -8.317
202009 -4.400 109.815 -5.330
202012 -1.800 109.897 -2.179
202103 -2.400 111.754 -2.857
202106 -3.200 114.631 -3.714
202109 -3.800 115.734 -4.368
202112 -3.200 117.630 -3.619
202203 -4.000 121.301 -4.387
202206 -4.600 125.017 -4.895
202209 -4.200 125.227 -4.462
202212 -4.000 125.222 -4.249
202303 -3.930 127.348 -4.105
202306 -3.050 128.729 -3.152
202309 -3.350 129.860 -3.432
202312 -3.110 129.419 -3.197
202403 -2.830 131.776 -2.857
202406 -2.890 132.554 -2.900
202409 -2.860 133.029 -2.860

Add all the adjusted EPS together and divide 10 will get our e10.


Oncternal Therapeutics  (NAS:ONCT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Oncternal Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncternal Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Executives
Robert James Wills director, officer: Executive Chairman 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Gunnar F. Kaufmann officer: Chief Scientific Officer C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Salim Yazji officer: Chief Medical Officer 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
James B Breitmeyer director, officer: President, CEO
Richard G Vincent officer: Chief Financial Officer C/O WOMEN FIRST HEALTH CARE, 5355 MIRA SORRENTO PLACE STE. 700, SAN DIEGO CA 92121-3825
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Rajesh Krishnan officer: Chief Technology Officer 12230 EL CAMINO, SUITE 300, SAN DIEGO CA 92130
Jinzhu Phd Chen director 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Michael G Carter director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
Hazel M Aker officer: General Counsel C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Shanghai Pharmaceutical (usa) Inc. 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS ROAD #821, SAN DIEGO CA 92130-2122
Shanghai Pharmaceuticals (hk) Investment Ltd 10 percent owner C/O ONCTERNAL THERAPEUTICS, INC., 12230 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130